体外研究：

细胞类型（Cell type）：Human leukemic cell line MT-2 cells

药物配制（Preparation）：Forskolinwas dissolved in DMSO to make stock solution.

实验方法（Assay）：MT-2 cells were seeded into 96-well plates at 5 × 104 cells per well. Cells were then pretreated for1 h with 1% DMSO (vehicle) or Fsk at 1, 5, 10, 25, 50, and 100 μM concentrations. The cells were stimulated with IL-2 as above and cultured for an additional 20 h at 37 °C. Control cells were treated with 1% DMSO for 20 h. During the final 4 h of incubation, the cells were pulsed with [3H]thymidine at a concentration of 0.5 μCi/200 μl. Cells were harvested onto fiberglass filters and analyzed using liquid scintillation counting.Fsk treatment inhibited the proliferation of MT-2 cells in a dose-dependent manner with an IC50 equal to∼5 μM Fsk. 

体内研究：

动物模型（Animal Model）：C57BL/6J mice and Mrp4-knockout mice

药物配制（Preparation）：Forskolin was dissolved in dimethyl sulfoxide (DMSO) and then diluted.

注射剂量（Dosages）：Forskolin was dissolved in DMSO and injected intraperitoneally into neonatal mice at postnatal days 4 (P4) (1.0 μg/50 μL (0.3 mg/kg))and 5 (P5)(1.5 μg/50 μL (0.5 mg/kg)). Mice injected with DMSO served as the controls. The treated mice were euthanized at P6, and their retinas were isolated for whole-mount immunohistochemistry (IHC)

给药途径（Administration）：Intraperitoneally (i.p.) Injection

体外研究：

细胞类型（Cell type）：Human leukemic cell line MT-2 cells

药物配制（Preparation）：Forskolinwas dissolved in DMSO to make stock solution.

实验方法（Assay）：MT-2 cells were seeded into 96-well plates at 5 × 104 cells per well. Cells were then pretreated for1 h with 1% DMSO (vehicle) or Fsk at 1, 5, 10, 25, 50, and 100 μM concentrations. The cells were stimulated with IL-2 as above and cultured for an additional 20 h at 37 °C. Control cells were treated with 1% DMSO for 20 h. During the final 4 h of incubation, the cells were pulsed with [3H]thymidine at a concentration of 0.5 μCi/200 μl. Cells were harvested onto fiberglass filters and analyzed using liquid scintillation counting.Fsk treatment inhibited the proliferation of MT-2 cells in a dose-dependent manner with an IC50 equal to∼5 μM Fsk. 

体内研究：

动物模型（Animal Model）：C57BL/6J mice and Mrp4-knockout mice

药物配制（Preparation）：Forskolin was dissolved in dimethyl sulfoxide (DMSO) and then diluted.

注射剂量（Dosages）：Forskolin was dissolved in DMSO and injected intraperitoneally into neonatal mice at postnatal days 4 (P4) (1.0 μg/50 μL (0.3 mg/kg))and 5 (P5)(1.5 μg/50 μL (0.5 mg/kg)). Mice injected with DMSO served as the controls. The treated mice were euthanized at P6, and their retinas were isolated for whole-mount immunohistochemistry (IHC)

给药途径（Administration）：Intraperitoneally (i.p.) Injection

体外研究：

细胞类型（Cell type）：Human leukemic cell line MT-2 cells

药物配制（Preparation）：Forskolinwas dissolved in DMSO to make stock solution.

实验方法（Assay）：MT-2 cells were seeded into 96-well plates at 5 × 104 cells per well. Cells were then pretreated for1 h with 1% DMSO (vehicle) or Fsk at 1, 5, 10, 25, 50, and 100 μM concentrations. The cells were stimulated with IL-2 as above and cultured for an additional 20 h at 37 °C. Control cells were treated with 1% DMSO for 20 h. During the final 4 h of incubation, the cells were pulsed with [3H]thymidine at a concentration of 0.5 μCi/200 μl. Cells were harvested onto fiberglass filters and analyzed using liquid scintillation counting.Fsk treatment inhibited the proliferation of MT-2 cells in a dose-dependent manner with an IC50 equal to∼5 μM Fsk. 

体内研究：

动物模型（Animal Model）：C57BL/6J mice and Mrp4-knockout mice

药物配制（Preparation）：Forskolin was dissolved in dimethyl sulfoxide (DMSO) and then diluted.

注射剂量（Dosages）：Forskolin was dissolved in DMSO and injected intraperitoneally into neonatal mice at postnatal days 4 (P4) (1.0 μg/50 μL (0.3 mg/kg))and 5 (P5)(1.5 μg/50 μL (0.5 mg/kg)). Mice injected with DMSO served as the controls. The treated mice were euthanized at P6, and their retinas were isolated for whole-mount immunohistochemistry (IHC)

给药途径（Administration）：Intraperitoneally (i.p.) Injection

体外研究：

细胞类型（Cell type）：Human leukemic cell line MT-2 cells

药物配制（Preparation）：Forskolinwas dissolved in DMSO to make stock solution.

实验方法（Assay）：MT-2 cells were seeded into 96-well plates at 5 × 104 cells per well. Cells were then pretreated for1 h with 1% DMSO (vehicle) or Fsk at 1, 5, 10, 25, 50, and 100 μM concentrations. The cells were stimulated with IL-2 as above and cultured for an additional 20 h at 37 °C. Control cells were treated with 1% DMSO for 20 h. During the final 4 h of incubation, the cells were pulsed with [3H]thymidine at a concentration of 0.5 μCi/200 μl. Cells were harvested onto fiberglass filters and analyzed using liquid scintillation counting.Fsk treatment inhibited the proliferation of MT-2 cells in a dose-dependent manner with an IC50 equal to∼5 μM Fsk. 

体内研究：

动物模型（Animal Model）：C57BL/6J mice and Mrp4-knockout mice

药物配制（Preparation）：Forskolin was dissolved in dimethyl sulfoxide (DMSO) and then diluted.

注射剂量（Dosages）：Forskolin was dissolved in DMSO and injected intraperitoneally into neonatal mice at postnatal days 4 (P4) (1.0 μg/50 μL (0.3 mg/kg))and 5 (P5)(1.5 μg/50 μL (0.5 mg/kg)). Mice injected with DMSO served as the controls. The treated mice were euthanized at P6, and their retinas were isolated for whole-mount immunohistochemistry (IHC)

给药途径（Administration）：Intraperitoneally (i.p.) Injection